Corticodentatonigral degeneration with neuronal achromasia

JJ Rebeiz, EH Kolodny, EP Richardson - Archives of neurology, 1968 - jamanetwork.com
IN RECENT years staff members of the Neurology Service at the Massachusetts General
Hospital have had the opportunity of examining three adult patients suffering from a slowly …

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

…, HC Andersson, P Kaplan, EH Kolodny… - The American journal of …, 2002 - Elsevier
… Kaplan MD d , Edwin H Kolodny MD e , Pramod Mistry MD f , Gregory Pastores MD e , Barry
E Rosenbloom MD g , C.Ronald Scott MD h , Rebecca S Wappner MD i , Ari Zimran MD j …

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L …

JE Wraith, LA Clarke, M Beck, EH Kolodny… - The Journal of …, 2004 - Elsevier
OBJECTIVE: To confirm the efficacy and safety of recombinant human α-L-iduronidase (laronidase)
in patients with mucopolysaccharidosis I (MPS I). STUDY DESIGN: This was a …

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

…, HC Andersson, P Kaplan, EH Kolodny… - Archives of internal …, 2000 - jamanetwork.com
Background The Gaucher Registry, the largest database of patients with Gaucher disease (GD)
worldwide, was initiated to better delineate the progressive nature of the disorder and …

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I

LA Clarke, JE Wraith, M Beck, EH Kolodny… - …, 2009 - publications.aap.org
OBJECTIVE. Our goal was to evaluate the long-term safety and efficacy of recombinant
human α-l-iduronidase (laronidase) in patients with mucopolysaccharidosis I. PATIENTS AND …

[PDF][PDF] Clinical phenotypes of different MPZ (P0) mutations may include Charcot–Marie–Tooth type 1B, Dejerine–Sottas, and congenital hypomyelination

LE Warner, MJ Hilz, SH Appel, JM Killian, EH Kolodny… - Neuron, 1996 - cell.com
Hereditary demyelinating peripheral neuropathies consist of a heterogeneous group of
genetic disorders that includes hereditary neuropathy with liability to pressure palsies (HNPP), …

Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy

…, J Kurtzberg, DA Wenger, EH Kolodny… - … England Journal of …, 1998 - Mass Medical Soc
Background Globoid-cell leukodystrophy is caused by a deficiency of galactocerebrosidase,
which results in progressive central nervous system deterioration. We investigated whether …

Long-term follow-up after gene therapy for canavan disease

…, SWJ McPhee, JS Francis, EH Kolodny… - Science translational …, 2012 - science.org
Canavan disease is a hereditary leukodystrophy caused by mutations in the aspartoacylase
gene (ASPA), leading to loss of enzyme activity and increased concentrations of the …

[HTML][HTML] Bone marrow–derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients …

…, S Dyhouse, R DeGasperi, EH Kolodny… - Experimental …, 1999 - Elsevier
Human bone marrow contains mesenchymal stem cells (MSCs) that can differentiate into
various cells of mesenchymal origin. We developed an efficient method of isolating and culture …

Newborn screening for Krabbe disease: the New York State model

…, RW Erbe, P Galvin-Parton, LE Helton, EH Kolodny… - Pediatric …, 2009 - Elsevier
Krabbe disease is a rare inherited neurologic disorder affecting the central and peripheral
nervous systems. The disease has four phenotypes: early infantile, later onset, adolescent, …